A citation-based method for searching scientific literature

S I Rothschild, R Nachbur, N Herzog, J R Passweg, M Pless. ESMO Open 2021
Times Cited: 1

List of co-cited articles
articles co-cited >1

Times Cited
  Times     Co-cited

Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Maya Gottfried, Jaafar Bennouna, Igor Bondarenko, Jean-Yves Douillard, David F Heigener, Maciej Krzakowski, Anders Mellemgaard, Silvia Novello, Sergei Orlov, Yvonne Summers,[...]. Target Oncol 2017

Molecular therapeutic targets in non-small cell lung cancer.
Kamya Sankar, Shirish M Gadgeel, Angel Qin. Expert Rev Anticancer Ther 2020

Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study.
Krittiya Korphaisarn, Pongwut Danchaivijitr, Thanyanan Reungwetwattana, Busayamas Chewaskulyong, Luangyot Thongthieang, Jarin Chindaprasirt, Kunlatida Maneenil, Chirawadee Sathitruangsak, Chanida Vinayanuwattikun. Front Oncol 2021

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Martin Reck, Rolf Kaiser, Anders Mellemgaard, Jean-Yves Douillard, Sergey Orlov, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao,[...]. Lancet Oncol 2014

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
Nick Thatcher, Alex Chang, Purvish Parikh, José Rodrigues Pereira, Tudor Ciuleanu, Joachim von Pawel, Sumitra Thongprasert, Eng Huat Tan, Kristine Pemberton, Venice Archer,[...]. Lancet 2005

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Tudor Ciuleanu, Lilia Stelmakh, Saulius Cicenas, Skaidrius Miliauskas, Alexandru Calin Grigorescu, Carina Hillenbach, Hrefna Kristin Johannsdottir, Barbara Klughammer, Emilio Esteban Gonzalez. Lancet Oncol 2012

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Frank Hilberg, Gerald J Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin-Chesa, Gerd Bader, Andreas Zoephel, Jens Quant,[...]. Cancer Res 2008

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.
Luis Corrales, Amanda Nogueira, Francesco Passiglia, Angela Listi, Christian Caglevic, Marco Giallombardo, Luis Raez, Edgardo Santos, Christian Rolfo. Front Med (Lausanne) 2017

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Martin Reck, Luis Paz-Ares, Paolo Bidoli, Federico Cappuzzo, Shaker Dakhil, Denis Moro-Sibilot, Hossein Borghaei, Melissa Johnson, Robert Jotte, Nathan A Pennell,[...]. Lung Cancer 2017

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?
Martin Reck, Keith M Kerr, Christian Grohé, Christian Manegold, Nick Pavlakis, Luis Paz-Ares, Rudolf M Huber, Sanjay Popat, Nick Thatcher, Keunchil Park,[...]. Future Oncol 2019

Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
E Giroux Leprieur, M Antoine, T Vieira, M Duruisseaux, V Poulot, N Rabbe, L Belmont, V Gounant, A Lavolé, B Milleron,[...]. Lung Cancer 2013

Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Bryan J Schneider, Sarah Temin, Sherman Baker, Julie Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2020

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018

Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
Martin Reck, Kostas Syrigos, Skaidrius Miliauskas, Sabine Zöchbauer-Müller, Jürgen R Fischer, Hannes Buchner, Thomas Kitzing, Rolf Kaiser, Dejan Radonjic, Keith Kerr. Lung Cancer 2020

Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen.
Céline Bouquet, Noël Lamandé, Marcus Brand, Jean-Marie Gasc, Betsy Jullienne, Gabrielle Faure, Franck Griscelli, Paule Opolon, Elisabeth Connault, Michel Perricaudet,[...]. Mol Ther 2006

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.